New drug can help stop certain breast cancer tumours early, trial shows
A trial called Serena-6 shows that camizestrant stops cancer cells from using hormones to grow, which helps patients stay well longer and delays the need for chemotherapy.
It is the first worldwide study to show that using blood tests to find early signs of cancer resistance to treatment helps patients, scientists say.
The study looked at patients who had hormone-positive, HER2-negative breast cancer, which is about 70% of cases.
The results of the Serena-6 trial represent more than a clinical milestone, they represent a transformational shift in how we approach precision medicine
Results showed patients given camizestrant reduced their chances of cancer progression by 56%, compared with just standard therapies.
Doctors used a simple blood test to spot changes in the cancer's DNA that show whether current treatments might soon stop working.
When they found these signs, some patients were given camizestrant, while others stayed on their usual treatment.
Those on camizestrant had their cancer stay the same and not get worse for much longer, 16 months on average, compared with about nine months for the others.
The drug was safe for most patients but 1% stopped taking it because of side effects.
More than 3,000 patients from 23 countries took part in the study, which was funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research in London.
This study is a clear example of how blood tests are starting to transform cancer treatment
Co-principal investigator Professor Nick Turner, group leader in molecular oncology at The Institute of Cancer Research, London, said the drug is 'a pivotal moment in breast cancer care'.
Professor Kristian Helin, chief executive of The Institute of Cancer Research said: 'The results of the Serena-6 trial represent more than a clinical milestone, they represent a transformational shift in how we approach precision medicine.'
The Serena-6 trial results were to be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on Sunday.
Dr Catherine Elliott, director of research at Cancer Research UK, said: 'This study is a clear example of how blood tests are starting to transform cancer treatment.
'By tracking tiny traces of tumour DNA in the blood, researchers were able to spot early signs of treatment resistance and switch therapies before cancer had a chance to grow.
'It shows how circulating tumour DNA, or ctDNA, could help doctors make smarter, more timely treatment decisions.
'This approach could become an important part of how we personalise care for people with advanced breast cancer.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Times
03-08-2025
- Irish Times
AstraZeneca's potential exit raises alarm for UK markets
AstraZeneca chief executive Pascal Soriot isn't confirming or denying reports that the UK's largest listed company is considering moving its primary stock market listing from London to New York. Yet recent remarks reveal where the company's future may lie. At AstraZeneca's half-year results press conference, Soriot gushed about the US, 'the country in our industry where innovation is taking place'. AstraZeneca is 'a very American company'. Soriot 'always believed in the great future of America' and, just to be sure no one missed the message, added: 'I definitely love America.' It plans to invest $50 billion in the US over five years, including building its largest-ever manufacturing facility in Virginia, and expects half its sales to come from the US by 2030. READ MORE While reaffirming its commitment to UK research sites such as Cambridge, Soriot stopped short of endorsing the London listing. His critique of Europe's low pharmaceutical investment and NHS pricing controls hints at wider tensions. The UK market has seen multiple major departures: CRH, Flutter, Arm and BHP. Pharmaceutical company Indivior left in July. Payment firm Wise is also saying farewell. In the past year 88 companies left the UK market, with another 70 already exiting in 2025, seeking higher valuations and liquidity in the US. AstraZeneca's exit would deal the biggest blow yet to the London Stock Exchange, so expect renewed calls for tax reform – especially 0.5 per cent stamp duty on shares – and regulatory easing. Otherwise, the argument goes, the Square Mile risks losing more ground to Wall Street.
Irish Examiner
22-07-2025
- Irish Examiner
AstraZeneca says new facility in Dublin on target for 2026 completion
Drug maker AstraZeneca has announced plans to invest $50bn (€42.6bn) in the US over the next five years amid the looming threat of US president Donald Trump's trade tariffs. The firm said the investment will fund a new "state-of-the-art" manufacturing facility in Virginia - set to be its largest single manufacturing investment in the world. It will also expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas. In 2021 AstraZeneca said it was investing €300m to establish a next-generation active pharmaceutical ingredient (API) manufacturing facility for small molecules in Dublin. Those plans are unaffected by the US announcement, a spokesperson told the Irish Examiner. "In line with our plans, the construction of our synthetic drug substance commercialisation facility in Ireland is scheduled for completion in 2026," said the spokesperson. The US announcement marks the latest by a global pharmaceutical giant to expand its footprint in the US as Mr Trump has threatened to impose tariffs of up to 20% on drug imports in an effort to increase manufacturing in America and drive down costs for Americans. AstraZeneca said the mammoth investment will create tens of thousands of jobs across the US, "powering growth and delivering next-generation medicines for patients in America and worldwide". The Anglo-Swedish group, which is listed on the FTSE 100, said the investment will also help it towards the group's target of reaching $80bn (€60bn) in revenues by 2030, with half of this is expected to come from the US, it added. Despite being headquartered in the UK, America is AstraZeneca's largest market, where it employs more than 18,000 staff and makes 42% of total group sales. It already has 19 R&D, manufacturing and commercial sites across the country.
RTÉ News
22-07-2025
- RTÉ News
AstraZeneca unveils $50 billion US investment as pharma tariff threat looms
AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the US by 2030, it said, the latest big investment by a pharmaceutical company reacting to President Donald Trump's tariff policy. The investment will fund a new drug manufacturing facility in Virginia and expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas, it said in a statement. It will also upgrade the Anglo-Swedish drugmaker's US clinical trial supply network and support ongoing investment in novel medicines. AstraZeneca said the expansion supports its ambition to reach $80 billion in annual revenue by 2030, with half coming from the US. The US accounted for more than 40% of AstraZeneca's annual revenue in 2024, and the company had been prioritising the market - the world's largest, worth $635 billion - before Trump's return to office. The move to scale up its US footprint is the latest by a drugmaker as Trump threatens to impose import tariffs on the industry and seeks to boost domestic manufacturing. The sector has historically been spared from trade disputes. Trump has called on pharma companies to make more of the medicines they sell in the US within the country, rather than importing active ingredients or finished medicines. He is also pushing for prices in the US to fall to what other countries pay. CEO Pascal Soriot announced the plans in Washington, saying he believes that drug prices need to rise elsewhere and "equalise" with other countries effectively contributing more to research and development costs. "The US cannot build or carry the cost of R&D for the entire world," he said. US Commerce Secretary Howard Lutnick's department is leading a probe into pharmaceutical imports that could pave the way for new tariffs. "For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness," said Lutnick in a statement issued by AstraZeneca. While Trump has repeatedly threatened tariffs on the sector, he signalled earlier this month that companies would be given a year to 18 months to "get their act together" before any levies take effect. The company said that the timing and location of the announcement was linked to the US policy environment, though some of the spending would have occurred regardless so that the infrastructure for future medicines was in place. The pledge is in addition to the $3.5 billion in investments the company announced in November 2024, the statement said. The $50 billion pledge matches the commitment announced by Swiss rival Roche in April and follows new spending plans unveiled this year by Eli Lilly & Co, Johnson & Johnson, Novartis and Sanofi. Also present at the announcement was Virginia State Governor Glenn Youngkin, a vocal Trump ally who has defended the administration's tariff policies. The new Virginia facility - the company's largest single manufacturing investment - will produce active ingredients for AstraZeneca's experimental weight-loss medicines, including its oral GLP-1 candidate and an oral PCSK9 inhibitor for cholesterol management, it said. The company said the investment could create tens of thousands of new jobs, but declined to give specifics. It employs about 18,000 people in the US and has a global workforce of about 90,000. In January it scrapped plans to invest £450m in its vaccine manufacturing plant in northern England, citing a cut in government support. Earlier this month, The Times reported the company was considering moving its stock market listing from London, where it is the exchange's most valuable company worth 159 billion pounds, to the US. The company declined to comment.
